https://orcid.org/0000-0001-8449-085X
References
- Tellez A, Ambrosioni J, Llopis J, Pericas JM, Falces C, Almela M, et al. Epidemiology, clinical features, and outcome of infective endocarditis due to Abiotrophia species and Granulicatella Species: report of 76 cases, 2000–2015. Clin Infect Dis. 2018;66:104–11.
- Ramos JN, dos Santos LS, Vidal LMR, Pereira PMA, Salgado AA, Fortes CQ, Vieira VV, Mattos-Guaraldi AL, Júnior RH, Damasco PV, et al. A case report and literature overview: Abiotrophia defectiva aortic valve endocarditis in developing countries. Infection. 2014;42(3):579–84.
- Birlutiu V, Birlutiu RM. Endocarditis due to Abiotrophia defectiva, a biofilm-related infection associated with the presence of fixed braces: a case report. Medicine. 2017;96(46):e8756.
- Prasidthrathsint K, Fisher MA. Antimicrobial susceptibility patterns among a large, nationwide cohort of Abiotrophia and Granulicatella clinical isolates. J Clin Microbiol. 2017;55(4):1025–31.
- Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–128.
- Alberti MO, Hindler JA, Humphries RM. Antimicrobial susceptibilities of Abiotrophia defectiva, Granulicatella adiacens, and Granulicatella elegans. Antimicrob Agents Chemother. 2016;60(3):1411–20.
- Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the american heart association. Circulation. 2015;132(15):1435–1486.
- Cervera C, Castañeda X, Pericas JM, del Río A, de la Maria CG, Mestres C, Falces C, Marco F, Moreno A, Miró JM, et al. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int J Antimicrob Agents. 2011;38(5):365–370.
- Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):202–210.
- Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel In Vitro PK/PD model of bacterial biofilm. Infect Dis Ther. 2015;4:51–65.
- Luther MK, Arvanitis M, Mylonakis E, LaPlante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother. 2014;58:4612–4620.
- Dominguez-Herrera J, Docobo-Perez F, Lopez-Rojas R, Pichardo C, Ruiz-Valderas R, Lepe JA, et al. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 2012;56:613–617.
- Bishburg E, Ghuman D, Cohen A, Chan T, Nalmas S. Abiotrophia spp. and Staphylococcus epidermidis endocarditis treated with daptomycin. Sci World J. 2008;8:793–795.